Oliver Konanz

CFH Beteiligungsgesellschaft mbH (CFH) is the investment arm and a wholly-owned subsidiary Landesbank Baden-Württemberg. CFH was founded in 1996 and is headquartered in Leipzig on the eastern side of Germany. CFH manages private equity funds including regional funds focused on Saxony and venture capital funds. They also manage a portfolio of direct participations and a private equity fund of fund. In addition to their parent Sachsen Landesbank and the Government of Land Sachsen, their investors include large regional savings banks and European entities.

Aster Capital Partners SAS (Aster Capital) is the French venture capital investment subsidiary of Schneider Electric SA (XP: SU), a world-leading electricity management and industrial automation group. Formerly known as Schneider Electric Ventures SAS, the firm was founded by Jean-Marc Bally in 2000 and changed their name to Aster Capital in 2010. Located in Paris with a representative office in China, the firm manages a venture capital fund sponsored by Schneider Electric and cooperates closely with the group's research scientists.

Süd KB Unternehmensbeteiligungs GmbH (Süd KB) is part of the private equity arm of Süd Beteiligungen GmbH, a wholly-owned subsidiary of LBBW-Landesbank Baden-Württermberg, a government-controlled regional bank based in southwestern Germany with head offices in Stuttgart, Karlsruhe and Mannheim. LBBW has a strong presence among small and medium-sized German companies. Established in 2000, Süd KB is based in Stuttgart.

Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany.

Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany.